Multidisciplinary approach to patient with malignant melanoma

Giuseppina Della Vittoria Scarpati, Celeste Fusciello, Francesco Sabbatino, Soldano Ferrone, Francesco Caponigro, Francesco Perri, Chiara Carlomagno, Stefano Pepe

Research output: Contribution to journalArticle

Abstract

The incidence of melanoma is rapidly increasing worldwide and the prognosis of patients with metastatic disease is still poor, with a median survival of 8-9 months and a 3-year overall survival (OS) rate less than 15% [1,2]. A complete surgical excision is the main treatment for primary cutaneous melanoma [3], but controversies about the extension of excision margins still remain [4]. Sentinel lymph node biopsy (SLNB) provides important prognostic and staging data by the identification of regional node-negative patients who would not benefit from a complete nodal dissection. However, there is no consensus in the definition of melanoma thickness to enforce the execution of the SLNB [5]. To date, Interferon-α (IFN-α)is the only approved adjuvant treatment after surgical excision of high-risk melanoma, but its indication remains still controversial [2,6].

Original languageEnglish
Pages (from-to)887-900
Number of pages14
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume13
Issue number6
DOIs
Publication statusPublished - 2013

Fingerprint

Melanoma
Sentinel Lymph Node Biopsy
Interferons
Dissection
Survival Rate
Skin
Survival
Incidence
Therapeutics

Keywords

  • B-RAF inibithors
  • Chemotherapy
  • Immunotherapy
  • Melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pharmacology

Cite this

Scarpati, G. D. V., Fusciello, C., Sabbatino, F., Ferrone, S., Caponigro, F., Perri, F., ... Pepe, S. (2013). Multidisciplinary approach to patient with malignant melanoma. Anti-Cancer Agents in Medicinal Chemistry, 13(6), 887-900. https://doi.org/10.2174/18715206113139990079

Multidisciplinary approach to patient with malignant melanoma. / Scarpati, Giuseppina Della Vittoria; Fusciello, Celeste; Sabbatino, Francesco; Ferrone, Soldano; Caponigro, Francesco; Perri, Francesco; Carlomagno, Chiara; Pepe, Stefano.

In: Anti-Cancer Agents in Medicinal Chemistry, Vol. 13, No. 6, 2013, p. 887-900.

Research output: Contribution to journalArticle

Scarpati, GDV, Fusciello, C, Sabbatino, F, Ferrone, S, Caponigro, F, Perri, F, Carlomagno, C & Pepe, S 2013, 'Multidisciplinary approach to patient with malignant melanoma', Anti-Cancer Agents in Medicinal Chemistry, vol. 13, no. 6, pp. 887-900. https://doi.org/10.2174/18715206113139990079
Scarpati, Giuseppina Della Vittoria ; Fusciello, Celeste ; Sabbatino, Francesco ; Ferrone, Soldano ; Caponigro, Francesco ; Perri, Francesco ; Carlomagno, Chiara ; Pepe, Stefano. / Multidisciplinary approach to patient with malignant melanoma. In: Anti-Cancer Agents in Medicinal Chemistry. 2013 ; Vol. 13, No. 6. pp. 887-900.
@article{8a5249cdd01f43a680e7c56276d77b30,
title = "Multidisciplinary approach to patient with malignant melanoma",
abstract = "The incidence of melanoma is rapidly increasing worldwide and the prognosis of patients with metastatic disease is still poor, with a median survival of 8-9 months and a 3-year overall survival (OS) rate less than 15{\%} [1,2]. A complete surgical excision is the main treatment for primary cutaneous melanoma [3], but controversies about the extension of excision margins still remain [4]. Sentinel lymph node biopsy (SLNB) provides important prognostic and staging data by the identification of regional node-negative patients who would not benefit from a complete nodal dissection. However, there is no consensus in the definition of melanoma thickness to enforce the execution of the SLNB [5]. To date, Interferon-α (IFN-α)is the only approved adjuvant treatment after surgical excision of high-risk melanoma, but its indication remains still controversial [2,6].",
keywords = "B-RAF inibithors, Chemotherapy, Immunotherapy, Melanoma",
author = "Scarpati, {Giuseppina Della Vittoria} and Celeste Fusciello and Francesco Sabbatino and Soldano Ferrone and Francesco Caponigro and Francesco Perri and Chiara Carlomagno and Stefano Pepe",
year = "2013",
doi = "10.2174/18715206113139990079",
language = "English",
volume = "13",
pages = "887--900",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Multidisciplinary approach to patient with malignant melanoma

AU - Scarpati, Giuseppina Della Vittoria

AU - Fusciello, Celeste

AU - Sabbatino, Francesco

AU - Ferrone, Soldano

AU - Caponigro, Francesco

AU - Perri, Francesco

AU - Carlomagno, Chiara

AU - Pepe, Stefano

PY - 2013

Y1 - 2013

N2 - The incidence of melanoma is rapidly increasing worldwide and the prognosis of patients with metastatic disease is still poor, with a median survival of 8-9 months and a 3-year overall survival (OS) rate less than 15% [1,2]. A complete surgical excision is the main treatment for primary cutaneous melanoma [3], but controversies about the extension of excision margins still remain [4]. Sentinel lymph node biopsy (SLNB) provides important prognostic and staging data by the identification of regional node-negative patients who would not benefit from a complete nodal dissection. However, there is no consensus in the definition of melanoma thickness to enforce the execution of the SLNB [5]. To date, Interferon-α (IFN-α)is the only approved adjuvant treatment after surgical excision of high-risk melanoma, but its indication remains still controversial [2,6].

AB - The incidence of melanoma is rapidly increasing worldwide and the prognosis of patients with metastatic disease is still poor, with a median survival of 8-9 months and a 3-year overall survival (OS) rate less than 15% [1,2]. A complete surgical excision is the main treatment for primary cutaneous melanoma [3], but controversies about the extension of excision margins still remain [4]. Sentinel lymph node biopsy (SLNB) provides important prognostic and staging data by the identification of regional node-negative patients who would not benefit from a complete nodal dissection. However, there is no consensus in the definition of melanoma thickness to enforce the execution of the SLNB [5]. To date, Interferon-α (IFN-α)is the only approved adjuvant treatment after surgical excision of high-risk melanoma, but its indication remains still controversial [2,6].

KW - B-RAF inibithors

KW - Chemotherapy

KW - Immunotherapy

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=84880146885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880146885&partnerID=8YFLogxK

U2 - 10.2174/18715206113139990079

DO - 10.2174/18715206113139990079

M3 - Article

C2 - 23272971

AN - SCOPUS:84880146885

VL - 13

SP - 887

EP - 900

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

SN - 1871-5206

IS - 6

ER -